Francis Y F Lee

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Overcoming kinase resistance in chronic myeloid leukemia
    Francis Lee
    Bristol Myers Squibb, 206 Provence Line Road, Princeton, NJ 08543, USA
    Int J Biochem Cell Biol 40:334-43. 2008
  2. pmc Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
    Xi De Wang
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, New Jersey, 08543, USA
    Genome Biol 8:R255. 2007
  3. doi request reprint Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models
    Francis Y F Lee
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Clin Cancer Res 14:8123-31. 2008
  4. doi request reprint Preclinical discovery of ixabepilone, a highly active antineoplastic agent
    Francis Y F Lee
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Cancer Chemother Pharmacol 63:157-66. 2008
  5. doi request reprint Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
    Francis Y F Lee
    Oncology Drug Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, K22 03, Princeton, NJ 08540, USA
    Cancer Chemother Pharmacol 63:201-12. 2009
  6. ncbi request reprint The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
    John S Tokarski
    Bristol Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, USA
    Cancer Res 66:5790-7. 2006
  7. ncbi request reprint N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
    Raj N Misra
    Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, New Jersey 08543 4000, USA
    J Med Chem 47:1719-28. 2004
  8. doi request reprint Metabolism and disposition of dasatinib after oral administration to humans
    Lisa J Christopher
    Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Drug Metab Dispos 36:1357-64. 2008
  9. ncbi request reprint Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models
    Veeraswamy Manne
    Oncology Drug Discovery and Discovery Chemistry, Bristol Myers Squibb Company Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Cancer Res 64:3974-80. 2004
  10. doi request reprint BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
    Joan M Carboni
    Oncology Drug Discovery, Department of Pharmaceutical Candidate Organization, Bristol Myers Squibb Company, PO Box 5400, Princeton, NJ 08543, USA
    Mol Cancer Ther 8:3341-9. 2009

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Overcoming kinase resistance in chronic myeloid leukemia
    Francis Lee
    Bristol Myers Squibb, 206 Provence Line Road, Princeton, NJ 08543, USA
    Int J Biochem Cell Biol 40:334-43. 2008
    ..The development of agents that effectively inhibit T315I mutations suggests that future treatment options will include combination therapy...
  2. pmc Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
    Xi De Wang
    Pharmaceutical Research Institute, Bristol Myers Squibb, Princeton, New Jersey, 08543, USA
    Genome Biol 8:R255. 2007
    ..To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to identify potential molecular markers for patient stratification and efficacy monitoring...
  3. doi request reprint Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models
    Francis Y F Lee
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Clin Cancer Res 14:8123-31. 2008
    ..We investigated the potential of ixabepilone, the first in a new class of antineoplastic agents known as epothilones, to synergize with antiangiogenic agents to inhibit tumor growth...
  4. doi request reprint Preclinical discovery of ixabepilone, a highly active antineoplastic agent
    Francis Y F Lee
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Cancer Chemother Pharmacol 63:157-66. 2008
    ..Ixabepilone combination therapy showed significantly superior progression-free survival and tumor responses over capecitabine alone...
  5. doi request reprint Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
    Francis Y F Lee
    Oncology Drug Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, K22 03, Princeton, NJ 08540, USA
    Cancer Chemother Pharmacol 63:201-12. 2009
    ..This study extends previous findings regarding the efficacy of ixabepilone and its low susceptibility to tumor resistance mechanisms and describes the pharmacokinetics of this new antineoplastic agent...
  6. ncbi request reprint The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
    John S Tokarski
    Bristol Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, USA
    Cancer Res 66:5790-7. 2006
    ..The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants...
  7. ncbi request reprint N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
    Raj N Misra
    Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, New Jersey 08543 4000, USA
    J Med Chem 47:1719-28. 2004
    ..c./i.p. A2780 human ovarian carcinoma xenograft model...
  8. doi request reprint Metabolism and disposition of dasatinib after oral administration to humans
    Lisa J Christopher
    Department of Pharmaceutical Candidate Optimization, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540, USA
    Drug Metab Dispos 36:1357-64. 2008
    ....
  9. ncbi request reprint Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models
    Veeraswamy Manne
    Oncology Drug Discovery and Discovery Chemistry, Bristol Myers Squibb Company Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Cancer Res 64:3974-80. 2004
    ..We developed a highly sensitive San-1 murine xenograft tumor model that is particularly useful for evaluating the in vivo activity of cytostatic FTIs such as BMS-225975...
  10. doi request reprint BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
    Joan M Carboni
    Oncology Drug Discovery, Department of Pharmaceutical Candidate Organization, Bristol Myers Squibb Company, PO Box 5400, Princeton, NJ 08543, USA
    Mol Cancer Ther 8:3341-9. 2009
    ..These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents...
  11. ncbi request reprint Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection
    Fei Huang
    Departments of Clinical Discovery and Oncology Discovery, Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    Cancer Res 67:2226-38. 2007
    ..Our results implicate that dasatinib may represent a valuable treatment option in this difficult-to-treat population. To test this hypothesis, clinical studies are now under way to determine the activity of dasatinib in these patients...
  12. ncbi request reprint Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors
    Louis J Lombardo
    Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543 4000, United States
    Bioorg Med Chem Lett 15:1895-9. 2005
    ..BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study...
  13. ncbi request reprint SAR and pH stability of cyano-substituted epothilones
    Alicia Regueiro-Ren
    Divisions of Discovery Chemistry, Oncology Drug Discovery and Pharmaceutical Development, Bristol Myers Squibb Pharmaceutical Research Institute, P O Box 4000, Princeton, New Jersey 08543 4000, USA
    Org Lett 4:3815-8. 2002
    ..12-Cyano epothilone 24 has improved pH stability over epothilone B, and its activity further supports the hypothesis that C-12 stereochemistry is not critical for tubulin affinity...
  14. ncbi request reprint Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
    Warren Fiskus
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Clin Cancer Res 12:5869-78. 2006
    ....
  15. ncbi request reprint Dasatinib induces a response in malignant thymoma
    Charles Chuah
    J Clin Oncol 24:e56-8. 2006
  16. ncbi request reprint Apoptotic pathways of epothilone BMS 310705
    Denise Uyar
    The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 91:173-8. 2003
    ..Using an early passage cell culture model derived from the ascites of a patient clinically refractory to platinum/paclitaxel therapy, we evaluated the pathway of caspase-mediated apoptosis...